| pubmed-article:21181615 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21181615 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:21181615 | lifeskim:mentions | umls-concept:C0278627 | lld:lifeskim |
| pubmed-article:21181615 | lifeskim:mentions | umls-concept:C0221912 | lld:lifeskim |
| pubmed-article:21181615 | lifeskim:mentions | umls-concept:C1705413 | lld:lifeskim |
| pubmed-article:21181615 | lifeskim:mentions | umls-concept:C1152564 | lld:lifeskim |
| pubmed-article:21181615 | lifeskim:mentions | umls-concept:C2916831 | lld:lifeskim |
| pubmed-article:21181615 | lifeskim:mentions | umls-concept:C1273870 | lld:lifeskim |
| pubmed-article:21181615 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:21181615 | pubmed:dateCreated | 2010-12-24 | lld:pubmed |
| pubmed-article:21181615 | pubmed:abstractText | Molecular targeted therapies - particularly epidermal growth factor receptor inhibitors (EGFRi) and multi tyrosine kinase-inhibitors (MTKi) - continually gain importance in oncology treatment. Adverse events differ greatly from those of conventional chemotherapy; especially cutaneous adverse events often constitute dose-limiting or therapy-limiting events. Knowledge of possible adverse events and close interaction between the dermatologist, the oncologist and the patient's family physician, a detailed patient education and a well-founded adverse event management are mandatory for the treatment with EGFRi and MTKi. Interdisciplinary outpatient clinics specialised on the treatment of these adverse events assist with the treatment of severe cases, the development of new therapeutic strategies and are essential for the concomitant treatment of patients treated with new targeted drugs within clinical trials. | lld:pubmed |
| pubmed-article:21181615 | pubmed:language | ger | lld:pubmed |
| pubmed-article:21181615 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21181615 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21181615 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21181615 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21181615 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21181615 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21181615 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:21181615 | pubmed:issn | 1439-4413 | lld:pubmed |
| pubmed-article:21181615 | pubmed:author | pubmed-author:SchulerMM | lld:pubmed |
| pubmed-article:21181615 | pubmed:author | pubmed-author:ZimmerLL | lld:pubmed |
| pubmed-article:21181615 | pubmed:author | pubmed-author:SchadendorfDD | lld:pubmed |
| pubmed-article:21181615 | pubmed:author | pubmed-author:LivingstoneEE | lld:pubmed |
| pubmed-article:21181615 | pubmed:author | pubmed-author:TrarbachTT | lld:pubmed |
| pubmed-article:21181615 | pubmed:copyrightInfo | © Georg Thieme Verlag KG Stuttgart · New York. | lld:pubmed |
| pubmed-article:21181615 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21181615 | pubmed:volume | 136 | lld:pubmed |
| pubmed-article:21181615 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21181615 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21181615 | pubmed:pagination | 39-44 | lld:pubmed |
| pubmed-article:21181615 | pubmed:meshHeading | pubmed-meshheading:21181615... | lld:pubmed |
| pubmed-article:21181615 | pubmed:meshHeading | pubmed-meshheading:21181615... | lld:pubmed |
| pubmed-article:21181615 | pubmed:meshHeading | pubmed-meshheading:21181615... | lld:pubmed |
| pubmed-article:21181615 | pubmed:meshHeading | pubmed-meshheading:21181615... | lld:pubmed |
| pubmed-article:21181615 | pubmed:meshHeading | pubmed-meshheading:21181615... | lld:pubmed |
| pubmed-article:21181615 | pubmed:meshHeading | pubmed-meshheading:21181615... | lld:pubmed |
| pubmed-article:21181615 | pubmed:meshHeading | pubmed-meshheading:21181615... | lld:pubmed |
| pubmed-article:21181615 | pubmed:meshHeading | pubmed-meshheading:21181615... | lld:pubmed |
| pubmed-article:21181615 | pubmed:meshHeading | pubmed-meshheading:21181615... | lld:pubmed |
| pubmed-article:21181615 | pubmed:meshHeading | pubmed-meshheading:21181615... | lld:pubmed |
| pubmed-article:21181615 | pubmed:meshHeading | pubmed-meshheading:21181615... | lld:pubmed |
| pubmed-article:21181615 | pubmed:meshHeading | pubmed-meshheading:21181615... | lld:pubmed |
| pubmed-article:21181615 | pubmed:meshHeading | pubmed-meshheading:21181615... | lld:pubmed |
| pubmed-article:21181615 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21181615 | pubmed:articleTitle | [Interdisciplinary management of cutaneous adverse events of EGFR inhibitors and multityrosine kinase inhibitors in oncology]. | lld:pubmed |
| pubmed-article:21181615 | pubmed:affiliation | Klinik für Dermatologie und Hauttumorzentrum, Universitätsklinikum Essen. | lld:pubmed |
| pubmed-article:21181615 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21181615 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:21181615 | pubmed:publicationType | Review | lld:pubmed |
